MedTrace Logo

A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831

NCT03538522 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2020-06-30

No results posted yet for this study

Summary

This study seeks to evaluate the efficacy and safety of NA-83 in subjects with mild cognitive impairment due to Alzheimer's Disease

Conditions

Interventions

DRUG

N-831(Traneurocin) 10 mg QD

Oral administration of 10 mg capsule of NA-831 QD for 24 weeks

DRUG

NA-831 (Traneurocin) 20 mg QD

Oral administration of 20 mg capsule of NA-831 QD for 24 weeks

DRUG

NA-831 (Traneurocin) 40 mg QD

Oral administration of 40 mg capsule of NA-831 QD or for 24 weeks

DRUG

Placebo oral capsule QD

Oral administration of oral placebo capsule QD or 24 weeks

Sponsors & Collaborators

  • Biomed Industries, Inc.

    lead INDUSTRY

Principal Investigators

  • Lloyd Tran, PhD · Biomed Industries, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-15
Primary Completion
2019-09-30
Completion
2019-10-30

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03538522 on ClinicalTrials.gov